Provided by Tiger Trade Technology Pte. Ltd.

Exelixis

54.64
+0.19000.35%
Post-market: 54.640.00000.00%16:33 EDT
Volume:2.23M
Turnover:121.41M
Market Cap:13.54B
PE:17.18
High:55.02
Open:54.10
Low:53.43
Close:54.45
52wk High:57.57
52wk Low:33.76
Shares:247.78M
Float Shares:214.00M
Volume Ratio:1.21
T/O Rate:1.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.18
EPS(LYR):2.78
ROE:44.39%
ROA:23.97%
PB:7.34
PE(LYR):19.65

Loading ...

U.S. Research Roundup-caseys General Stores, Micron Technology, SAP

Reuters
·
Jun 25

Exelixis is Maintained at Market Outperform by Citizens

Dow Jones
·
Jun 24

Exelixis Colorectal Cancer Data Underwhelms: Gerberry Maintains Sell/Underperform with Price Target Below Current Share Price

TIPRANKS
·
Jun 23

Exelixis announces results from final analysis of phase 3 STELLAR-303 trial

TIPRANKS
·
Jun 22

Exelixis says STELLAR-303 trial misses statistical significance for survival in metastatic colorectal cancer non-liver subgroup

Reuters
·
Jun 22

Exelixis Provides Update on the Phase 3 Stellar-303 Trial Evaluating Zanzalintinib in Combination With an Immune Checkpoint Inhibitor in Patients With Metastatic Colorectal Cancer

THOMSON REUTERS
·
Jun 22

Exelixis - No New Safety Signals Identified for Zanzalintinib Plus Atezolizumab in Nlm Subgroup

THOMSON REUTERS
·
Jun 22

How Investors Are Reacting To Exelixis (EXEL) CABOMETYX Neuroendocrine Tumor Phase 3 Win at ASCO

Simply Wall St.
·
Jun 17

How Broad CABOMETYX PFS Benefit At Exelixis (EXEL) Has Changed Its Investment Story

Simply Wall St.
·
Jun 07

Exelixis director Jack L. Wyszomierski sells 3,925 common shares for $198,408.75

Reuters
·
Jun 04

Exelixis director Sue Gail Eckhardt sells 9,812 shares for $491,974.68

Reuters
·
Jun 04

Exelixis announces results from subgroup analysis of Phase 3 Cabinet trial

TIPRANKS
·
May 31

Exelixis - Cabometyx Reduces Risk of Progression or Death by 74% in Non-Functional Net, 60% in Functional Net

THOMSON REUTERS
·
May 30

Exelixis Shareholders Approve Equity Plan and Board Slate

TIPRANKS
·
May 30

Exelixis shareholders approve amended, restated 2017 equity incentive plan at annual meeting

Reuters
·
May 30

Top Exelixis Insider Makes a Major Move With Company Stock

TIPRANKS
·
May 29

Exelixis EVP R&D Aftab Dana disposes of 43,451 common shares for $2.19 million

Reuters
·
May 29

Movement Alert|Exelixis Rises 5.54% in Regular Trading, Trading at $52.88

Market Focus
·
May 29

Exelixis (EXEL) Valuation Check After ASCO 2026 Data Spotlight And New Merck Trial Collaboration

Simply Wall St.
·
May 28

Exelixis to webcast investor conference fireside chats in June

Reuters
·
May 28